期刊
CHILDREN-BASEL
卷 8, 期 10, 页码 -出版社
MDPI
DOI: 10.3390/children8100837
关键词
asymmetric dimethylarginine; biomarker; dimethylamine; kidney disease; nitric oxide; children; dimethylarginine dimethylaminohydrolase; protein arginine methyl transferase; pediatric nephrology
类别
资金
- Ministry of Science and Technology, Taiwan [MOST 110-2314-B-182A-029]
- Chang Gung Memorial Hospital, Kaohsiung, Taiwan [CMRPG8K0721, CMRPG8K0722]
This review summarizes the levels of circulating and urinary ADMA in children and adolescents with kidney disease, as well as its pathophysiological role in the kidneys. Additionally, various analytical methods for measuring ADMA and the issues that need to be addressed before clinical implementation are discussed.
Asymmetric dimethylarginine (ADMA), an endogenous nitric oxide (NO) synthase inhibitor, inhibits NO synthesis and contributes to the pathogenesis of many human diseases. In adults, ADMA has been identified as a biomarker for chronic kidney disease (CKD) progression and cardiovascular risk. However, little attention is given to translating the adult experience into the pediatric clinical setting. In the current review, we summarize circulating and urinary ADMA reported thus far in clinical studies relating to kidney disease in children and adolescents, as well as systematize the knowledge on pathophysiological role of ADMA in the kidneys. The aim of this review is also to show the various analytical methods for measuring ADMA and the issues tht need to be addressed before transforming to clinical practice in pediatric medicine. The last task is to suggest that ADMA may not only be suitable as a diagnostic or prognostic biomarker, but also a promising therapeutic strategy to treat pediatric kidney disease in the future.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据